These complementary approaches then suggested active gastritis, which correlates with TLR5, and phosphorylated S6K1, a substrate of mTOR, as the most practical surrogate markers for responses to H. pylori eradication therapy. The gene discussed is RPS6KB1; the disease is gastritis.